1. Home
  2. ROL vs GMAB Comparison

ROL vs GMAB Comparison

Compare ROL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rollins Inc.

ROL

Rollins Inc.

HOLD

Current Price

$35.31

Market Cap

22.6B

Sector

Finance

ML Signal

HOLD

GMAB

Genmab A/S ADS

HOLD

Current Price

$32.65

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROL
GMAB
Founded
1948
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.6B
20.3B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
ROL
GMAB
Price
$35.31
$32.65
Analyst Decision
Buy
Strong Buy
Analyst Count
11
8
Target Price
$64.73
$39.56
AVG Volume (30 Days)
4.0M
2.2M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.32%
N/A
EPS Growth
13.54
N/A
EPS
0.52
N/A
Revenue
$2,161,220,000.00
N/A
Revenue This Year
$10.42
$17.85
Revenue Next Year
$8.86
$16.04
P/E Ratio
$66.79
$1.90
Revenue Growth
7.23
N/A
52 Week Low
$34.35
$23.62
52 Week High
$66.14
$35.43

Technical Indicators

Market Signals
Indicator
ROL
GMAB
Relative Strength Index (RSI) 39.42 52.38
Support Level N/A $32.54
Resistance Level $37.73 $34.44
Average True Range (ATR) 0.73 0.59
MACD 0.09 -0.32
Stochastic Oscillator 33.81 20.00

Price Performance

Historical Comparison
ROL
GMAB

About ROL Rollins Inc.

Rollins is a global leader in route-based pest control services, with operations primarily in the United States and across North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US and Canada, with near-national coverage. It also has a portfolio of other brands, which it uses to reach customers through alternative sales channels. Residential pest and termite prevention accounts for the majority of Rollins' services, reflecting its ongoing focus on the US and Canadian markets.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: